Abstract |
The palliative efficacy of strontium-89 chloride has been evaluated in a prospective double-blind crossover study comparing it with stable strontium as placebo in 32 patients with prostate cancer metastatic to bone. Response was assessed 5 weeks after each treatment. 26 patients were evaluable. Complete pain relief was only reported following strontium-89 injection. Statistical comparison between placebo and strontium-89 showed clear evidence of a therapeutic response to strontium-89 compared with only a limited placebo effect (P less than 0.01).
|
Authors | V J Lewington, A J McEwan, D M Ackery, R J Bayly, D H Keeling, P M Macleod, A T Porter, M A Zivanovic |
Journal | European journal of cancer (Oxford, England : 1990)
(Eur J Cancer)
Vol. 27
Issue 8
Pg. 954-8
( 1991)
ISSN: 0959-8049 [Print] England |
PMID | 1716935
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
|
Topics |
- Aged
- Bone Neoplasms
(radiotherapy, secondary)
- Double-Blind Method
- Humans
- Male
- Middle Aged
- Pain
(prevention & control)
- Palliative Care
- Platelet Count
(radiation effects)
- Prospective Studies
- Prostatic Neoplasms
(radiotherapy)
- Strontium Radioisotopes
(therapeutic use)
|